Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience

References

• Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18(1):75–84, viii.
   PubMedGoogle Scholar
• Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–1885.
   PubMed Web of Science ®Google Scholar
• Dunavoelgyi R, Dieckmann K, Gleiss A, et al. Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007 [Evaluation Studies]. Int J Radiat Oncol Biol Phys. 2012;83(1):121–128.
   PubMed Web of Science ®Google Scholar
• Furdova A, Babal P, Kobzova D, et al. Uveal melanoma survival rates after single dose stereotactic radiosurgery. Neoplasma. 2018;65(6):965–971.
   PubMed Web of Science ®Google Scholar
• Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients [Comparative Study Meta-Analysis Systematic Review]. Acta Ophthalmol Scand. 1999;77(4):414–417.
   PubMedGoogle Scholar
• Konstantinidis L, Groenewald C, Coupland SE, et al. Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol. 2014;98(1):82–85.
   PubMed Web of Science ®Google Scholar
• Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients [Research Support, Non-U.S. Gov't]. Ophthalmology. 2004;11(5):977–983.
   Web of Science ®Google Scholar
• Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–1693.
   PubMedGoogle Scholar
• Damato BE. Treatment selection for uveal melanoma. Dev Ophthalmol. 2012;49:16–26.
   PubMedGoogle Scholar
• Dunavoelgyi R, Dieckmann K, Gleiss A, et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys. 2011;81(1):199–205.
   PubMed Web of Science ®Google Scholar
• Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62(5):1405–1411.
   PubMed Web of Science ®Google Scholar
• Yeh H, Matanoski GM, Wang N, et al. Cancer incidence after childhood nasopharyngeal radium irradiation: a follow-up study in Washington County, Maryland [Research Support, Non-U.S. Gov't Research Support, U. Am J Epidemiol. 2001;153(8):749–756.
   PubMed Web of Science ®Google Scholar
• Aziz HA, Singh AD. Radiation chorioretinopathy: evidence for effective therapy. Int Ophthalmol Clin. 2015;55(1):53–61. Winter
   PubMedGoogle Scholar
• Damato B, Patel I, Campbell IR, et al. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas [Research Support, Non-U.S. Gov't]. Int J Radiat Oncol Biol Phys. 2005; 63(2):392–400.
   PubMed Web of Science ®Google Scholar
• Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma [Research Support, Non-U. Invest Ophthalmol Vis Sci. 2003;44(11):4651–4659.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma [Research Support, Non-U.S. Govt]. Ophthalmology. 1991;98(3):383–389. discussion 390.
   PubMed Web of Science ®Google Scholar
• Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119(8):1582–1589.
   PubMed Web of Science ®Google Scholar
• Krema H, Heydarian M, Beiki-Ardakani A, et al. A comparison between ¹²125Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma . Br J Ophthalmol. 2013;97(3):327–332.
   PubMed Web of Science ®Google Scholar
• Caminal JM, Mejia K, Masuet-Aumatell C, et al. Endoresection versus iodine-125 plaque brachytherapy for the treatment of choroidal melanoma [Comparative Study]. Am J Ophthalmol. 2013;156(2):334–342 e1.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, et al. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992;99(5):760–766.
   PubMed Web of Science ®Google Scholar
• Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001;51(1):138–147.
   PubMed Web of Science ®Google Scholar
• Dieckmann K, Bogner J, Georg D, et al. A linac-based stereotactic irradiation technique of uveal melanoma. Radiother Oncol. 2001;61(1):49–56.
   PubMed Web of Science ®Google Scholar
• Zehetmayer M, Dieckmann K, Kren G, et al. Fractionated stereotactic radiotherapy with linear accelerator for uveal melanoma-preliminary Vienna results. Strahlenther Onkol. 1999;175 Suppl 2(Suppl 2):74–75.
   PubMed Web of Science ®Google Scholar
• Kidd MN, Lyness RW, Patterson CC, et al. Prognostic factors in malignant melanoma of the choroid: a retrospective survey of cases occurring in Northern Ireland between 1965 and 1980. Trans Ophthalmol Soc U K. 1986;105(Pt 1):114–121.
   PubMedGoogle Scholar
• Petersch B, Bogner J, Dieckmann K, et al. Automatic real-time surveillance of eye position and gating for stereotactic radiotherapy of uveal melanoma [Clinical Trial]. Med Phys. 2004;31(12):3521–3527.
   PubMed Web of Science ®Google Scholar
• Georg D, Dieckmann K, Bogner J, et al. Impact of a micromultileaf collimator on stereotactic radiotherapy of uveal melanoma [Evaluation Studies]. Int J Radiat Oncol Biol Phys. 2003;55(4):881–891.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Pintilie M. Analysing and interpreting competing risk data. Statist Med. 2007;26(6):1360–1367.
   PubMed Web of Science ®Google Scholar
• Pintilie M. Competing risks a practical perspective. Wiley; 2006.
   Google Scholar
• Muller K, Nowak PJ, de Pan C, et al. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2005;63(1):116–122.
   PubMed Web of Science ®Google Scholar
• Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65(3):780–787.
   PubMed Web of Science ®Google Scholar
• Modorati G, Miserocchi E, Galli L, et al. Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol. 2009;93(1):40–44.
   PubMed Web of Science ®Google Scholar
• Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma [Research Support, Non-U.S. Br J Ophthalmol. 2013;97(7):804–811.
   PubMed Web of Science ®Google Scholar
• Vonk DT, Kim Y, Javid C, et al. Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review. Brachytherapy. 2015;14(5):726–733.
   PubMed Web of Science ®Google Scholar
• Verschueren KM, Creutzberg CL, Schalij-Delfos NE, et al. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol. 2010;95(3):332–338.
   PubMed Web of Science ®Google Scholar
• Seibel I, Cordini D, Rehak M, et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol. 2015;160(4):628–636.
   PubMed Web of Science ®Google Scholar
• Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma [Review]. Int J Radiat Oncol Biol Phys. 2003;55(4):867–880.
   PubMed Web of Science ®Google Scholar
• Bellocq D, Roy P, Kodjikian L, et al. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas. Melanoma Res. 2018.
   Web of Science ®Google Scholar
• van den Aardweg GJ, Naus NC, Verhoeven AC, et al. Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines [Comparative Study Research Support, Non-U.S. Gov't]. Invest Ophthalmol Vis Sci. 2002;43(8):2561–2565.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't. Arch Ophthalmol. 2000;118(6):773–778.
   PubMed Web of Science ®Google Scholar
• Gigliotti CR, Modorati G, Di Nicola M, et al. Predictors of radio-induced visual impairment after radiosurgery for uveal melanoma. Br J Ophthalmol. 2018;102(6):833–839.
   PubMed Web of Science ®Google Scholar
• Kiuchi T, Tatsuzaki H, Wakabayashi T, et al. Long-term changes in rabbit cornea after ionizing radiation. Cornea. 2004;23(8 Suppl):S87–S90.
   PubMedGoogle Scholar
• Gunduz K, Shields CL, Shields JA, et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma [Research Support, Non-U.S. Gov't]. Arch Ophthalmol. 1999;17(5):609–614.
   Google Scholar
• Seibel I, Cordini D, Hager A, et al. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1787–1792.
   PubMed Web of Science ®Google Scholar
• Dunavoelgyi R, Georg D, Zehetmayer M, et al. Dose-response of critical structures in the posterior eye segment to hypofractioned stereotactic photon radiotherapy of choroidal melanoma. Radiother Oncol. 2013;108(2):348–353.
   PubMed Web of Science ®Google Scholar
• Lane AM, Kim IK, Gragoudas ES. Proton irradiation for peripapillary and parapapillary melanomas [Research Support, Non-U. Arch Ophthalmol. 2011;129(9):1127–1130.
   PubMedGoogle Scholar
• Somani S, Sahgal A, Krema H, et al. Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: 2-year follow-up. Can J Ophthalmol. 2009;44(1):61–65.
   PubMed Web of Science ®Google Scholar
• Kim IK, Lane AM, Egan KM, et al. Natural history of radiation papillopathy after proton beam irradiation of parapapillary melanoma [Research Support, Non-U.S. Gov't]. Ophthalmology. 2010;117(8):1617–1622.
   PubMed Web of Science ®Google Scholar
• Akbaba S, Foerster R, Nicolay NH, et al. Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma. Radiat Oncol. 2018;13(1):140.
   PubMed Web of Science ®Google Scholar